読み込み中
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
前日終値
$1.68
−$0.08 · -4.55%
日中の時刻はETです。市場データは遅延する場合があります。
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
日中レンジ
現在 $1.68
52週レンジ
現在 $1.68
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
75
割安
センチメント
55
まちまち
リスク
53
やや高いリスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
日中レンジ
現在 $1.68
52週レンジ
現在 $1.68
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4980.3万 USD | 3108.1万 USD | 120.4万 USD | 13.9万 USD | 29.8万 USD |
| 売上原価 | 27.4万 USD | 61.6万 USD | 5897.2万 USD | 5251.6万 USD | 5504.6万 USD |
| 粗利益 | 4952.9万 USD | 3046.5万 USD | −5776.8万 USD | −5237.7万 USD | −5474.8万 USD |
| 研究開発 | 6112.1万 USD | 8448万 USD | 5888.7万 USD | 5281.6万 USD | 5504.6万 USD |
| 販売・一般管理 | 3731.9万 USD | 1.32億 USD | — | — | — |
| 営業費用 | 9844万 USD | 2.28億 USD | 1.14億 USD | 4838.3万 USD | 3234.2万 USD |
| 受取利息 | 690.9万 USD | 1229.3万 USD | 773.2万 USD | 159.6万 USD | 13.4万 USD |
| 支払利息 | 833.9万 USD | 1557.9万 USD | 1310.1万 USD | 278万 USD | 80.2万 USD |
| 減価償却費と償却費 | 62.1万 USD | 53.4万 USD | 55.4万 USD | 42.7万 USD | 29.2万 USD |
| 営業利益 | −4891.1万 USD | −1.97億 USD | −1.72億 USD | −1.01億 USD | −8709万 USD |
| 純利益 | −5034.1万 USD | −2億 USD | −1.77億 USD | −1.02億 USD | −8775.8万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$6.00
上昇余地（257.14%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2015年5月21日 | 1:7 | — | — |
発効済み 2015年5月21日
1:7
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1593.82万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1057.83万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF590.81万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO370.98万0.03%139.17億 USD0.24%$356.78+0.94%
State Street SPDR S&P Pharmaceuticals ETFXPH361.18万0.78%4.62億 USD0.35%$64.65+1.60%
Vanguard Russell 2000 ETFVTWO322.24万0.02%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA197.15万0.01%218.24億 USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT145.19万0.01%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
